Patented drug products revenue share Canada 1990-2022

This statistic displays the annual sales contribution of patented drug products in Canadian drug market from 1990 to 2022. In 2017, the patented drugs contributed more than 61 percent of sales to the Canadian drug market. However, in 2022, the contribution was, for the first time since 1996, below 50 percent.

Patented drugs sales contribution in total Canadian drug market from 1990 to 2022

Characteristic	Sales share in percentage
2022	49%
2021	51%
2020	55.4%
2019	57.5%
2018	59%
2017	61.5%
2016	60.8%
2015	61.6%
2014	59.9%
2013	60.7%
2012	59.2%
2011	58.3%
2010	55.8%
2009	59.6%
2008	61.7%
2007	63.2%
2006	67.8%
2005	70.6%
2004	72.2%
2003	72.7%
2002	67.4%
2001	65%
2000	63%
1999	61%
1998	55.1%
1997	52.3%
1996	45%
1995	43.9%
1994	40.7%
1993	44.4%
1992	43.8%
1991	43.2%
1990	43.2%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

February 2024

More information

Region

Canada

Survey time period

1990 to 2022

Supplementary notes

Note : The denominator in this ratio comprises sales of patented, non-patented brand and generic drug products. Starting with the estimate for 2005, this value is derived from data contained in IQVIA’s MIDAS™ database. In previous years, IMS data were used to calculate sales of generic drug products only, while sales of non-patented brand products were estimated from data submitted by patentees. This approach was abandoned because of anomalies related to year-to-year changes in the set of companies reporting to the PMPRB. Ratios reported for years before 2005 likely overstate the patented share, but by only a small amount. This small bias in no way invalidates the strong upward trend evinced by the results for the years 1990 through 2003. Ratios since 2009 have also been revised slightly as a result of data updates from IQVIA - none of these adjustments resulted in a change greater than 0.4%.

Citation formats